Winton Group LTD Bluebird Bio, Inc. Transaction History

Winton Group LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	BUY	$2.94 - $5.23 $90,590 - $161,151	30,813 New	30,813 $128,000
Q4 2018 Feb 05, 2019	SELL	$59.1 - $93.26 $86,640 - $136,719	-1,466 Closed	0 $0
Q3 2018 Nov 02, 2018	SELL	$88.86 - $117.49 $28,701 - $37,949	-323 Reduced 18.05%	1,466 $0
Q2 2018 Aug 20, 2018	SELL	$99.64 - $127.59 $72,239 - $92,502	-725 Reduced 28.84%	1,789 $0
Q1 2018 May 21, 2018	BUY	$105.8 - $150.94 $265,981 - $379,463	2,514 New	2,514 $0

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $28.5M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

Stay updated on Winton Group LTD with notifications on news.